U42 RR16578/RR/NCRR NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
2006	1
2007	3
2008	2
2009	1
2011	1
2012	1
2024	0

1

The continuing contribution of gene marking to cell and gene therapy.

Tey SK, Brenner MK. Tey SK, et al. Mol Ther. 2007 Apr;15(4):666-76. doi: 10.1038/sj.mt.6300109. Epub 2007 Feb 13. Mol Ther. 2007. PMID: 17299400 Free article. Review.

2

Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation.

Leen AM, Christin A, Myers GD, Liu H, Cruz CR, Hanley PJ, Kennedy-Nasser AA, Leung KS, Gee AP, Krance RA, Brenner MK, Heslop HE, Rooney CM, Bollard CM. Leen AM, et al. Blood. 2009 Nov 5;114(19):4283-92. doi: 10.1182/blood-2009-07-232454. Epub 2009 Aug 21. Blood. 2009. PMID: 19700662 Free PMC article. Clinical Trial.

3

Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant.

Sili U, Leen AM, Vera JF, Gee AP, Huls H, Heslop HE, Bollard CM, Rooney CM. Sili U, et al. Cytotherapy. 2012 Jan;14(1):7-11. doi: 10.3109/14653249.2011.636963. Cytotherapy. 2012. PMID: 22172091 Free PMC article.

4

Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy.

Leen AM, Christin A, Khalil M, Weiss H, Gee AP, Brenner MK, Heslop HE, Rooney CM, Bollard CM. Leen AM, et al. J Virol. 2008 Jan;82(1):546-54. doi: 10.1128/JVI.01689-07. Epub 2007 Oct 17. J Virol. 2008. PMID: 17942545 Free PMC article.

5

Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy.

Fujita Y, Leen AM, Sun J, Nakazawa Y, Yvon E, Heslop HE, Brenner MK, Rooney CM. Fujita Y, et al. J Immunother. 2008 Sep;31(7):665-74. doi: 10.1097/CJI.0b013e318181b4bd. J Immunother. 2008. PMID: 18600178 Free PMC article.

6

Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals.

Leen AM, Myers GD, Sili U, Huls MH, Weiss H, Leung KS, Carrum G, Krance RA, Chang CC, Molldrem JJ, Gee AP, Brenner MK, Heslop HE, Rooney CM, Bollard CM. Leen AM, et al. Nat Med. 2006 Oct;12(10):1160-6. doi: 10.1038/nm1475. Epub 2006 Sep 24. Nat Med. 2006. PMID: 16998485

7

Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer.

Bollard CM, Gottschalk S, Leen AM, Weiss H, Straathof KC, Carrum G, Khalil M, Wu MF, Huls MH, Chang CC, Gresik MV, Gee AP, Brenner MK, Rooney CM, Heslop HE. Bollard CM, et al. Blood. 2007 Oct 15;110(8):2838-45. doi: 10.1182/blood-2007-05-091280. Epub 2007 Jul 3. Blood. 2007. PMID: 17609424 Free PMC article. Clinical Trial.

8

Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epstein-Barr virus-associated lymphoma.

Bollard CM, Gottschalk S, Helen Huls M, Leen AM, Gee AP, Rooney CM. Bollard CM, et al. Cytotherapy. 2011 May;13(5):518-22. doi: 10.3109/14653249.2011.561983. Epub 2011 Mar 1. Cytotherapy. 2011. PMID: 21361747 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Results by year